V
Viatris Inc. (VTRS)
NMS – Real vaqt narxi. Valyuta: USD
17.17
+0.25 (1.48%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NMS – Real vaqt narxi. Valyuta: USD
17.17
+0.25 (1.48%)
Yopilishda: May 12, 2026, 4:00 PM EDT
Viatris Inc. o'z sho'ba korxonalari bilan birgalikda Shimoliy Amerika, Yevropa, Xitoy, Tayvan, Gonkong, Yaponiya, Avstraliya, Yangi Zelandiya, Osiyoning qolgan qismi, Afrika, Lotin Amerikasi va Yaqin Sharqdagi sog'liqni saqlash kompaniyasi sifatida faoliyat yuritadi. U to'rtta segmentda ishlaydi: Rivojlangan bozorlar, Katta Xitoy, JANZ va Rivojlanayotgan bozorlar. Kompaniya retsept bo'yicha sotiladigan brendli dori vositalari, generik dori vositalari, murakkab generik dori vositalari va biosimilar mahsulotlarni taklif etadi. Shuningdek, u yurak-qon tomir, O'RK va anesteziya, dermatologiya, diabet va metabolizm, ko'z kasalliklari, gastroenterologiya, immunologiya, onkologiya, shuningdek, respirator va allergik kasalliklar kabi turli xil yuqumli bo'lmagan va yuqumli kasalliklarni qamrab oluvchi turli terapevtik sohalarda dori vositalarini, shuningdek, bemorlarga o'z sog'lig'ini yaxshiroq boshqarishga yordam beradigan diagnostika klinikalari, ta'limiy seminarlar va raqamli vositalar kabi qo'llab-quvvatlash xizmatlarini taqdim etadi. Bundan tashqari, kompaniya og'iz orqali qabul qilinadigan qattiq dozalar, in'ektsiyalar va murakkab dozalash shakllarida dori vositalarini chakana va dorixona muassasalariga, ulgurji savdogarlar va distribyutorlarga, to'lovchilar, sug'urtachilar va hukumatlarga, hamda muassasalarga taqdim etadi. U o'z mahsulotlarini Lyrica, Lipitor, Celebrex, Viagra, Creon, Influvac, Wixela Inhub, EpiPen Auto-Injector, Fraxiparine, Yupelri, Norvasc, Amitiza, Effexor, Lipacreon, Zoloft, Xalabrands, Dymista, Xanax va Breyna brendlari ostida farmatsevtik ulgurji savdogarlar/distribyutorlar, farmatsevtik chakana savdogarlar, muassasa dorixonalari, pochta va elektron tijorat dorixonalari hamda maxsus dorixonalar orqali tarqatadi. Kompaniya uzoq muddatli glatiramer asetatli depolash mahsulotlari va qo'shimcha mahsulotlarni ishlab chiqish va tijoratlashtirish bo'yicha Mapi Pharma Ltd. bilan; BOTOX brendli biologik mahsulotning biosimilarini ishlab chiqish, ishlab chiqarish va tijoratlashtirish bo'yicha Revance Therapeutics, Inc. bilan; hamda revefenacinni ishlab chiqish va tijoratlashtirish bo'yicha Theravance Biopharma, Inc. bilan hamkorlik shartnomalariga ega. Viatris Inc. 1961 yilda tashkil etilgan va shtab-kvartirasi Pensilvaniya shtatining Kanonsburg shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Corinne M. Le Goff M.B.A., Pharm.D. | Chief Commercial Officer |
| Dr. Hemanth Jacob Varghese CFA, Ph.D. | Chief Strategy Officer |
| Mr. Andrew Enrietti | Chief Administrative & Transformation Officer |
| Mr. Matthew Joseph Maletta | Chief Legal Officer |
| Mr. Peter McCormick | Chief Supply Officer |
| Mr. Philippe Martin | Chief R&D Officer |
| Mr. Ramkumar V. Rayapureddy | Chief Information Officer |
| Mr. Scott Andrew Smith Ph.D. | CEO & Director |
| Mr. William Szablewski C.F.A. | Head of Investor Relations & Capital Markets |
| Ms. Lara Ramsburg | Chief People & Corporate Affairs Officer |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-07 | 8-K | vtrs-20260507.htm |
| 2026-05-07 | 10-Q | vtrs-20260331.htm |
| 2026-05-04 | 8-K | ef20072373_8k.htm |
| 2026-04-02 | DEFA14A | ny20062029x772_defa14a.htm |
| 2026-02-26 | 8-K | vtrs-20260223.htm |
| 2026-02-26 | 10-K | vtrs-20251231.htm |
| 2026-02-03 | 8-K | ef20064574_8k.htm |
| 2025-12-08 | 8-K | ef20060770_8k.htm |
| 2025-12-05 | 8-K | ef20060767_8k.htm |
| 2025-11-06 | 8-K | vtrs-20251106.htm |